单侧声带照射治疗T1a声门癌的可行性
本研究纳入34例临床T1aN0M0声门鳞状细胞癌患者,接受仅照射单侧声带的放疗。中位随访41.3个月,3年与5年局部控制率均为96.8%,2例(6%)出现3级放射性皮炎,无严重晚期毒性。作者认为单侧声带照射局部控制好、急慢性毒性低、嗓音恢复合理,可作为T1a声门癌的可行治疗策略。
要点
- T1a声门癌单侧声带照射的3年与5年局部控制率均为96.8%。
- 急性严重毒性为2例(6%)3级放射性皮炎,随访未见严重晚期毒性。
- 单侧声带照射可作为T1a声门癌的可行治疗选择。
核心结论
- 单侧声带照射治疗T1a声门癌显示出良好的局部控制、较低的急性和晚期毒性以及合理的嗓音恢复,可作为可行治疗策略。
研究设计与样本
- 单中心纳入34例临床T1aN0M0声门鳞状细胞癌患者,接受单侧声带放疗,分析治疗结局与毒性。
- 中位随访41.3个月(范围6.4-124.5个月)。
主要发现
- 3年与5年局部控制率均为96.8%。
- 2例(6%)患者出现3级放射性皮炎这一严重急性毒性。
- 随访期间无患者发生严重晚期毒性事件。
关键数值与推荐
- 局部控制率:3年96.8%,5年96.8%。
- 严重急性毒性:3级放射性皮炎2例(6%)。
- 严重晚期毒性:无。
临床怎么用
- 对临床T1aN0M0声门鳞状细胞癌,可考虑单侧声带照射以缩小照射范围并降低毒性。
- 治疗前需评估分期为T1a,治疗后随访关注局部控制与嗓音恢复。
局限性
- 样本量34例,随访时间范围跨度大,未设对照组,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Generally, radiotherapy for patients with early glottic cancer includes treatment of the whole larynx. This study was conducted to evaluate the treatment outcomes and toxicity in patients who received single vocal cord irradiation (SVCI) for T1a classification glottic cancer. METHODS: A total of 34 patients diagnosed with clinical T1aN0M0 classification squamous cell carcinoma of the glottis who received radiotherapy to the single vocal cord were included for analysis. RESULTS: Median follow-up period was 41.3 months (range, 6.4-124.5 months). The 3-year and 5-year local control (LC) rates were both 96.8%. Grade 3 radiation dermatitis was observed as severe acute toxicity in two (6%) patients. No patients experienced any severe late toxicity events during follow-up. CONCLUSIONS: SVCI showed good LC, low acute and late toxicities, and reasonable voice recovery. SVCI may be considered a feasible treatment strategy for patients with T1a glottic cancer.
引用
- Chung SY, Lee CG. Feasibility of single vocal cord irradiation as a treatment strategy for T1a glottic cancer. Head Neck. 2019. PMID: 31854475. doi:10.1002/hed.26052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。